DATE: March 15, 2006

RE: CLARIFICATION MEMO #4 for PACTG P1059: New shipping information for enhanced culture/latency studies

TO: Pediatric PACTG PIs & Study Coordinators at Sites Participating in PACTG P1059

FROM: PACTG P1059 Protocol Team

The following serves as Clarification Memo #4 for PACTG P1059 "A Phase I, Open-Label Study to Evaluate the Safety and Tolerability of Recombinant HIV-1 Vaccines in HIV-1 Infected Young Adults with Control of HIV-1 Replication and on Stable Highly Active Antiretroviral Therapy (HAART)", version 1.0, dated January 31, 2005. This Clarification Memo is available from the P1059 protocol specific web page on the Pediatric ACTG Website (http://pactg.s-3.com). The username is: pactg and the password is: cure (all lower case).

This memo is being issued to notify sites of a new shipping address, phone and fax number for the enhanced culture/latency studies. This change applies to Appendix V of the protocol, page 2 of 2. Effective immediately, the new address, phone and fax are:

Dr. Deborah Persaud
Johns Hopkins University School of Medicine
Ross Building, Room 1170
720 Rutland Avenue
Baltimore, MD 21205
Phone: 443-287-3733
FAX: 410-614-1315
Email: dpers@jhmi.edu

This information will be added to the next version of the protocol. Please contact the protocol team at actg.teamp1059@fstrf.org if you have any questions.

Thank you for your participation in PACTG P1059.